<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Unipolar depression in adults: Choosing treatment for resistant depression
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Unipolar depression in adults: Choosing treatment for resistant depression
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Unipolar depression in adults: Choosing treatment for resistant depression
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Thase, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            K Ryan Connolly, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter P Roy-Byrne, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H6076917">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients presenting with unipolar major depression (major depressive disorder) do not recover after their initial treatment. As an example, one prospective observational study found that among 3671 outpatients who were treated with
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         , remission occurred in only 37 percent [
         <a href="#rid1">
          1
         </a>
         ]. In addition, patients who fail their initial treatment often do not respond to subsequent trials and frequently experience chronic depression, impaired psychosocial functioning, and poor overall general health [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         This topic reviews choosing a specific treatment for resistant depression. Other topics discuss the general principles of treating resistant depression; the epidemiology, risk factors, assessment, and prognosis of treatment-resistant depression; the initial treatment of depression; and the clinical features and diagnosis of depression.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/119986.html" rel="external">
          "Unipolar depression in adults: General principles of treating resistant depression"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/87498.html" rel="external">
          "Unipolar treatment-resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/91774.html" rel="external">
          "Unipolar depression in adults: Clinical features"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H96382263">
         <span class="h1">
          DEFINITIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unipolar major depression
         </strong>
         – Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode  (
         <a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">
          table 1
         </a>
         ) and have no history of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 2
         </a>
         ) or hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. A major depressive episode is a period lasting at least two weeks, with five or more of the following symptoms, at least one of which is depressed mood or anhedonia: depressed mood, anhedonia, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration or memory, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide. Additional information about the clinical presentation and diagnosis of major depressive disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/91774.html" rel="external">
          "Unipolar depression in adults: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment-resistant depression
         </strong>
         – The term “treatment-resistant depression” typically refers to major depressive episodes that do not respond satisfactorily after two trials of antidepressant monotherapy at sufficient doses for sufficient duration; however, the definition has not been standardized [
         <a href="#rid4">
          4
         </a>
         ]. The definition of treatment-resistant depression is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/87498.html" rel="external">
          "Unipolar treatment-resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis", section on 'Treatment-resistant depression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29355597">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general principles and issues that are involved in treating resistant depression in adults include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Confirming the diagnosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbidity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adherence with treatment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment strategies
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonspecific care management
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Duration of an adequate drug trial
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Referral
        </p>
        <p>
        </p>
        <p>
         These general principles are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/119986.html" rel="external">
          "Unipolar depression in adults: General principles of treating resistant depression"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8046352">
         <span class="h1">
          MILD TO MODERATE DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Determining the severity of a depressive syndrome has not been standardized. The three paragraphs immediately below describe different means of establishing severity, in descending order of preference.
        </p>
        <p>
         Mild to moderate unipolar major depression is indicated by a score &lt;20 points on the Patient Health Questionnaire – Nine Item (PHQ-9)  (
         <a class="graphic graphic_table graphicRef59307" href="/z/d/graphic/59307.html" rel="external">
          table 4
         </a>
         ). The PHQ-9 is a self-report assessment that is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14860.html" rel="external">
          "Using scales to monitor symptoms and treat depression (measurement based care)", section on 'Patient Health Questionnaire - Nine Item'
         </a>
         .)
        </p>
        <p>
         Alternatively, one study classified episodes of major depression as mild to moderate in those individuals who had only five to seven of the nine symptoms that define major depression  (
         <a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. This is consistent with the approach used in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Many studies have assessed severity of depression using clinician-administered instruments, such as the Hamilton Rating Scale for Depression  (
         <a class="graphic graphic_table graphicRef72220" href="/z/d/graphic/72220.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ] or Montgomery-Asberg Depression Rating Scale  (
         <a class="graphic graphic_figure graphicRef62945 graphicRef67951 graphicRef81162" href="/z/d/graphic/62945.html" rel="external">
          figure 1A-C
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. However, these rating scales are generally not used as part of standard care.
        </p>
        <p>
         Mild to moderate major depression is characterized by the following clinical features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No suicidal or homicidal ideation or behavior is present. If suicidal ideation is present, it does not pose an imminent risk; examples include the wish or hope that death will overtake oneself (eg, “Life is not worth living” or “I would be better off dead”); or fleeting thoughts of killing oneself, with nonexistent or vague plans to commit suicide and no intent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No psychotic features (eg, delusions or hallucinations).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Little to no aggressiveness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intact judgment such that the patient or others are not at imminent risk of being harmed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impaired functioning is not obvious.
        </p>
        <p>
        </p>
        <p>
         Mild to moderate depression can generally be treated in an outpatient or partial (day) hospital program setting.
        </p>
        <p class="headingAnchor" id="H4456801">
         <span class="h2">
          Treatment algorithm
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with treatment-resistant, unipolar major depression, treatment strategies include augmentation (adding a treatment) and switching treatment (eg, switching antidepressants) [
         <a href="#rid8">
          8-11
         </a>
         ]. Regardless of which strategy is used, we make one change at a time, which allows us to better understand whether a particular therapeutic is helpful.
        </p>
        <p>
         For mild to moderate unipolar major depression that is treatment resistant, our general approach is as follows  (
         <a class="graphic graphic_algorithm graphicRef142553" href="/z/d/graphic/142553.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest initially using augmentation interventions; some evidence suggests that the benefit of augmentation is modestly superior to switching antidepressants (see
         <a class="local">
          'Efficacy of primary treatment strategies'
         </a>
         below). Augmenting an antidepressant with a second drug may provide faster, complimentary, or synergistic effects, compared with switching antidepressants [
         <a href="#rid12">
          12
         </a>
         ]. In addition, augmentation avoids withdrawal symptoms that may arise when the initial antidepressant is discontinued. If patients do not respond to augmentation with a second drug, we then switch antidepressants (ie, administer monotherapy with a new antidepressant), or augment with or switch to psychotherapy or repetitive transcranial magnetic stimulation (TMS). This approach, augmentation followed by switching, is consistent with multiple treatment guidelines and systematic reviews [
         <a href="#rid9">
          9,13,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, it is reasonable to reverse the order of these treatment strategies and initially switch antidepressants. Some studies of treatment-resistant depression suggest that the benefits of switching and augmentation are comparable, and some patients may prefer antidepressant monotherapy [
         <a href="#rid10">
          10
         </a>
         ]. In addition, switching antidepressants may be preferable to augmentation because adherence is generally better with monotherapy than combination treatment [
         <a href="#rid15">
          15,16
         </a>
         ]. Monotherapy may also cost less and may be less likely to cause adverse events and drug-drug interactions, compared with adding a second drug [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment-resistant patients who cannot tolerate an adequate dose of the initial antidepressant, or who encounter drug-drug interactions, should initially switch antidepressants [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Given that the efficacy of augmentation is not clearly superior to switching antidepressants, shared decision making with patients is important. Patients who partially benefit from the initial antidepressant and experience few adverse effects generally prefer adjunctive pharmacotherapy rather than switching [
         <a href="#rid18">
          18
         </a>
         ]. Conversely, patients who experience less symptomatic improvement and more side effects with the antidepressant prescribed at first presentation typically prefer switching antidepressants. For treatment-resistant depression, multiple practice guidelines suggest either augmentation or switching [
         <a href="#rid9">
          9,11,13,19-23
         </a>
         ].
        </p>
        <p>
         Among patients with treatment-resistant depression who augment antidepressants with a second drug and do not respond, it is not clear how many trials of add-on therapy that clinicians should administer before switching the antidepressant. We generally provide one to three courses of augmentation before switching the antidepressant. When switching the antidepressant, we typically continue the current adjunctive drug, based upon the principle of making only one change at a time.
        </p>
        <p>
         Although monotherapy often causes fewer adverse effects than multidrug regimens [
         <a href="#rid24">
          24
         </a>
         ], this is not always the case. The prospective Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study compared side effects in 269 treatment-resistant patients who selected switching (from
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         to
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         ,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         , or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         ) as next-step treatment, and 269 patients who selected augmentation of citalopram (with bupropion or
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          buspirone
         </a>
         ); propensity scoring was used to match the two groups for potential confounders observed at baseline [
         <a href="#rid25">
          25
         </a>
         ]. The overall incidence of distressing side effects for each group was similar.
        </p>
        <p>
         For patients with treatment-resistant depression who initially switch antidepressants and do not respond, it is not clear how many trials of antidepressant monotherapy that clinicians should administer before augmenting the antidepressant with a second treatment. We generally provide one to three courses of next-step antidepressant monotherapy before using augmentation.
        </p>
        <p>
         An alternative to switching antidepressants or augmenting the antidepressant with a second medication is to switch from pharmacotherapy to psychotherapy (eg, cognitive-behavioral therapy [CBT]) or to TMS, or retain the initial antidepressant and add psychotherapy or TMS [
         <a href="#rid13">
          13,26,27
         </a>
         ]. In addition, it is reasonable to augment the initial antidepressant with both pharmacotherapy and psychotherapy. However, psychotherapy is often not available, and many patients decline it [
         <a href="#rid18">
          18
         </a>
         ]. The efficacy of switching to and augmenting with psychotherapy are each discussed elsewhere in this topic. (See
         <a class="local">
          'Psychotherapy'
         </a>
         below and
         <a class="local">
          'Psychotherapy'
         </a>
         below.)
        </p>
        <p>
         Implementation of augmentation and switching are discussed elsewhere in this topic. (See
         <a class="local">
          'Initial approach'
         </a>
         below and
         <a class="local">
          'Next step treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H904025">
         <span class="h3">
          Efficacy of primary treatment strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         For treatment-resistant depression, relatively few head-to-head randomized trials have compared augmentation with switching treatments. Although results across the trials are mixed, the most compelling evidence suggests that add-on therapy may be at least modestly superior to switching antidepressants:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 12-week, open-label, randomized trial enrolled patients (n = 1522; 85 percent male) with unipolar major depression who remained depressed despite treatment with at least one course of antidepressant therapy [
         <a href="#rid28">
          28
         </a>
         ]. Nearly half of the patients had comorbid posttraumatic stress disorder, and most patients were currently receiving psychotherapy. Patients were assigned to one of three treatment strategies: augment the current antidepressant with
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         (target dose 5 to 15 mg/day), augment with
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         sustained release (target dose 300 to 400 mg/day) or switch to bupropion monotherapy. The primary findings included the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Remission was statistically greater in the augment-aripiprazole group than the switch group, but the clinical difference was modest (29 versus 22 percent of patients). In the augment-bupropion group, remission occurred in 27 percent, which did not differ statistically from the other two groups. In patients 65 years and older, the benefit of augmentation with
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         vis a vis switching to
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         was more prominent (n = 226, 38 versus 21 percent) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who remitted during acute treatment (n = 396) received continuation treatment for another 24 weeks; relapse at week 36 was comparable for the three treatment groups (approximately 25 percent of patients in each group).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adverse effects that occurred more often in the augment-aripiprazole group, compared with the other two groups, included akathisia, somnolence, and weight gain, as well as multiple abnormal laboratory tests. As an example, at week 36, weight gain from baseline ≥7 percent occurred in 25 percent of the augment-aripiprazole group, compared with 5 percent in each of the other two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Anxiety occurred more often in the augment-bupropion group and the switch group, compared with the augment-aripiprazole group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One limitation of the study was attrition; during the 12-week acute phase, 25 percent of the patients withdrew from the study. Other limitations included the lack of blinding for patients and treating clinicians, as well as the predominantly male sample; major depression occurs twice as often in females than in males. Nevertheless, other randomized trials indicate that
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         augmentation may be more efficacious in females than in males [
         <a href="#rid30">
          30
         </a>
         ]; if true, the present study may have underestimated the benefit of aripiprazole augmentation [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another trial enrolled 96 patients (77 percent female) with unipolar major depression who did not respond to their initial antidepressant within six weeks and randomly assigned them to add-on treatment with
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         (mean dose 4 mg/day) or to switch antidepressants [
         <a href="#rid32">
          32
         </a>
         ]. Study treatments were administered for six weeks, and patients and treating clinicians were not blind to treatment. Remission occurred more often with aripiprazole augmentation than switching antidepressants (54 versus 20 percent of patients) and functioning also improved more with aripiprazole.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, tolerability appeared to be comparable, such that discontinuation of treatment due to adverse effects for augmentation and switching occurred in 6 and 10 percent of patients. Weight gain during the six weeks with augmentation and switching was 0.6 and 1.0 kg, and akathisia and sexual functioning in the two groups were also comparable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A third trial in treatment-resistant geriatric depression (n = 413 patients) also found that improvement was greater with
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         augmentation than switching to
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         More limited evidence suggests that for treatment-resistant depression, the benefits of augmenting with pharmacotherapy and switching antidepressants are comparable:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An eight-week randomized trial enrolled 375 patients and randomly assigned them to various therapies that included five augmentation options, two switch options, and continuing
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         monotherapy [
         <a href="#rid34">
          34,35
         </a>
         ]. Pooled remission rates for the augmentation and the switch strategies appeared to be comparable (37 and 41 percent; difference was not statistically tested).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple reviews that examined randomized, placebo-controlled trials of augmentation and separate randomized, placebo-controlled trials of switching concluded that the two strategies achieved comparable results [
         <a href="#rid36">
          36,37
         </a>
         ]. As an example, a pooled analysis in one review found that the mean rate of response (reduction of baseline symptoms ≥50 percent) for augmentation and switching was 38 and 40 percent [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective observational study compared outcomes in 269 patients who selected augmentation of
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         (with
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         or
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          buspirone
         </a>
         ) and 269 patients who selected switching (from citalopram to bupropion,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         , or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         ) as next-step treatment; propensity scoring was used to match the two groups for potential confounders observed at baseline [
         <a href="#rid39">
          39
         </a>
         ]. The probability of remission for the two groups was comparable.
        </p>
        <p>
        </p>
        <p>
         In some cases, switching antidepressants may be more efficacious than augmentation. One open-label, 10-week trial randomly assigned patients who did not remit with
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         (n = 112) to switch to
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         or to add-on treatment with
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         [
         <a href="#rid40">
          40
         </a>
         ]. Remission occurred in more patients who switched to imipramine than those who added mirtazapine (71 versus 39 percent).
        </p>
        <p class="headingAnchor" id="H2345508222">
         <span class="h2">
          Initial approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         For mild to moderate unipolar major depression that does not respond to an antidepressant, our initial approach generally relies upon augmentation interventions [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Standard augmentation strategies for managing treatment-resistant depression include pharmacotherapy and psychotherapy [
         <a href="#rid8">
          8
         </a>
         ]. The choice between the two is generally based upon availability and patient preference because there is no compelling evidence that one is superior to the other for acute outcomes [
         <a href="#rid42">
          42
         </a>
         ]. Pharmacotherapy is typically used for augmentation because it is more available and often preferred. However, patients acutely ill with unipolar major depression who improve with pharmacotherapy and subsequently discontinue it appear to be at greater risk for relapse, compared with patients who improve with and discontinue psychotherapy (eg, CBT). (See
         <a class="medical medical_review" href="/z/d/html/14674.html" rel="external">
          "Unipolar depression in adults: Continuation and maintenance treatment", section on 'Relapse/recurrence in the absence of treatment'
         </a>
         .)
        </p>
        <p>
         If augmentation with either pharmacotherapy or psychotherapy is not effective, add-on treatment with the other modality may be beneficial. In a trial of patients with unipolar major depression who were initially randomized to monotherapy for 12 weeks with an antidepressant or CBT, 112 did not remit and subsequently received augmentation with the other modality for another 12 weeks [
         <a href="#rid43">
          43
         </a>
         ]. Remission with combination treatment occurred in 62 percent.
        </p>
        <p>
         Another standard augmentation intervention for acute resistant depression is TMS. However, it is not known if maintenance treatment with TMS for unipolar major depression is beneficial.
        </p>
        <p>
         Treatment-resistant depression that is managed with add-on pharmacotherapy or psychotherapy may also benefit from supplementary interventions such as exercise [
         <a href="#rid44">
          44
         </a>
         ]. A 10-week randomized trial enrolled 42 patients with major depression who did not respond to at least six weeks of antidepressant treatment and compared adjunctive aerobic exercise (two sessions per week, each lasting one hour, in a physical therapy setting) with a single consultation focused upon advice for physical activity [
         <a href="#rid45">
          45
         </a>
         ]. Improvement of both depression and cardiovascular fitness was greater with exercise.
        </p>
        <p class="headingAnchor" id="H3759144534">
         <span class="h3">
          Pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with treatment-resistant depression who receive augmentation, drug-drug interactions between antidepressants and add-on medications (eg, second-generation antipsychotics,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , or triiodothyronine) are generally not a problem. However, combining a monoamine oxidase inhibitor (MAOI) with another antidepressant, such as a selective serotonin reuptake inhibitor (SSRI), can cause the serotonin syndrome or a hypertensive crisis [
         <a href="#rid12">
          12,46
         </a>
         ]. Specific interactions between an antidepressant and another medication may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p>
         Treatment-resistant patients who are treated with an add-on drug and do not respond within 6 to 12 weeks of reaching the target dose, or do not tolerate the combination, should be treated with a second medication combination. We suggest tapering and discontinuing the failed adjunctive medication over one to two weeks at the same time another adjunctive medication is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease. As an example,
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         15 mg per day is decreased by 5 mg per day every one to three days. At the same time, the antidepressant is continued at the same dose. However, it is reasonable to switch the antidepressant after the adjunctive drug has been switched. Switching antidepressants is discussed elsewhere in this topic. (See
         <a class="local">
          'Next step treatment'
         </a>
         below.)
        </p>
        <p>
         Lack of response to numerous standard treatments may impel clinicians to prescribe a relatively large number of concomitant medications (≥4 psychotropic drugs). However, we generally avoid complex medication regimens because there are no data supporting their utility, and patients may feel worse due to the cumulative side effects.
        </p>
        <p class="headingAnchor" id="H925759895">
         <span class="h4">
          Choosing a drug
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mild to moderate depression who are treatment resistant and receiving add-on pharmacotherapy, several options are available. The most widely studied drugs include [
         <a href="#rid8">
          8,28,36,47-52
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second-generation antipsychotics
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second antidepressant from a different class
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid hormone
        </p>
        <p>
        </p>
        <p>
         Our specific choice of add-on therapy depends primarily upon the patient’s values and preferences. Some patients may prioritize treatment efficacy, and others may prioritize tolerability and avoiding adverse effects. These approaches are described in the subsections below. (See
         <a class="local">
          'Patients who prioritize efficacy'
         </a>
         below and
         <a class="local">
          'Patients who prioritize tolerability'
         </a>
         below.)
        </p>
        <p>
         However, it is reasonable for clinicians to augment with any of these four pharmacotherapy options, because in the few head-to-head trials that compared different drugs, efficacy was generally comparable [
         <a href="#rid1">
          1,53
         </a>
         ]. As an example:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An eight-week randomized trial compared
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , paroxetine plus
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         , and paroxetine plus thyroid hormone in 140 treatment-resistant patients and found that remission was statistically comparable (27, 43, and 38 percent of patients) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A network meta-analysis of 48 randomized trials (n &gt;6000 depressed patients) evaluated the efficacy of augmentation agents by using results from direct comparisons between the drugs (in head-to-head trials), as well as indirectly comparing drugs through their relative effect with a common comparator (typically placebo) [
         <a href="#rid54">
          54
         </a>
         ]. Response (reduction of baseline symptoms ≥50 percent) or remission occurred more often with add-on
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , or thyroid hormone (T3 or T4), compared with placebo. However, among the active treatments, the relative benefits were comparable.
        </p>
        <p>
        </p>
        <p>
         Other factors to consider in choosing add-on pharmacotherapy include past response, safety, comorbid general medical conditions, adverse effects, ease of use, patient preference, and cost. As an example, patients with a history of extrapyramidal symptoms should avoid
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ; overweight patients should avoid
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ; patients with renal or thyroid disease should avoid
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ; and patients with compromised cardiovascular function should avoid thyroid hormone. In addition, adding a second antidepressant may involve fewer baseline laboratory tests and monitoring than adding an antipsychotic, lithium, or triiodothyronine.
        </p>
        <p class="headingAnchor" id="H3207044765">
         <span class="h5">
          Patients who prioritize efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with resistant depression who prioritize efficacy and can tolerate the initial antidepressant, we suggest augmenting antidepressants with a second-generation antipsychotic as first-step treatment and augmentation with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         for patients who do not respond to second-generation antipsychotics [
         <a href="#rid9">
          9,13,23
         </a>
         ]. Second-generation antipsychotics appear to better balance efficacy and tolerability than lithium. However, it is reasonable to first augment with lithium. Augmentation with a second-generation antipsychotic or lithium is consistent with practice guidelines [
         <a href="#rid9">
          9-11,13,23
         </a>
         ].
        </p>
        <p>
         The rationale for using second-generation antipsychotics or
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is that their efficacy is better established, compared with other drugs that are commonly used for augmentation, such as a second antidepressant or thyroid hormone. However, adverse effects also appear to be greater with second-generation antipsychotics and lithium, and it is thus reasonable to augment with a second antidepressant or thyroid hormone instead. (See
         <a class="local">
          'Patients who prioritize tolerability'
         </a>
         below.)
        </p>
        <p>
         In choosing a second-generation antipsychotic as augmentation for treatment-resistant depression, our general order of preference is as follows, based upon the evidence of benefits and harms:
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         , and less often,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         , or
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         [
         <a href="#rid42">
          42,49,54-58
         </a>
         ]. This recommended order is consistent with practice guidelines [
         <a href="#rid13">
          13
         </a>
         ]. However, few head-to-head trials have compared the second-generation antipsychotics for augmentation, and it is reasonable to use these drugs in a different sequence.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          Aripiprazole
         </a>
         is often used first because it appears to cause fewer side effects than other second-generation antipsychotics  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 6
         </a>
         ). If aripiprazole fails because of intolerance due to akathisia, we discontinue aripiprazole and initiate
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         , based upon studies that indicate akathisia occurs in approximately half as many patients taking brexpiprazole than aripiprazole [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Among second-generation antipsychotics that are used for depression, we typically avoid
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , especially for longer-term treatment (eg, ≥12 weeks), because it carries the highest risk of weight gain and diabetes [
         <a href="#rid60">
          60-62
         </a>
         ]. If olanzapine is to be used for augmentation, we suggest combining it samidorphan, which can mitigate weight gain [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         For patients with treatment-resistant depression who do not respond to one second-generation antipsychotic within 6 to 12 weeks of reaching the target dose, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one to two weeks while starting and titrating up a different second-generation antipsychotic at the same time. We generally attempt treatment with no more than two second-generation antipsychotics before augmenting with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy of second-generation antipsychotics
         </strong>
         – Multiple trials have demonstrated that adjunctive treatment with different second-generation antipsychotics can be efficacious for unipolar, nonpsychotic major depression that has not responded to antidepressant monotherapy [
         <a href="#rid14">
          14,49,54,64-66
         </a>
         ]. However, adverse effects and discontinuation of treatment are more likely with these drugs, compared with antidepressant monotherapy. In addition, most of the trials that studied the antipsychotics were funded by the manufacturer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence supporting augmentation with a second-generation antipsychotic includes an open-label, six-week randomized trial in patients with resistant major depression (n = 103), which compared augmentation of an SSRI with add-on
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         (mean dose 3 mg/day) or
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         (mean dose 199 mg/day) [
         <a href="#rid67">
          67
         </a>
         ]. Remission occurred in more patients who received adjunctive aripiprazole than bupropion (55 versus 34 percent). None of the patients discontinued treatment because of adverse events, and the incidence of extrapyramidal symptoms and of akathisia was comparable in the two groups. Other trials have demonstrated that response is greater in patients who receive add-on aripiprazole than bupropion [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, several placebo-controlled trials (mean duration seven weeks) have demonstrated that add-on second-generation antipsychotics can be efficacious for nonpsychotic, resistant, unipolar major depression:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A meta-analysis of 28 randomized trials in patients with who failed at least one course of antidepressant monotherapy (n &gt;7300) found that response was 40 percent greater with add-on second-generation antipsychotics than placebo (relative risk 1.4, 95% CI 1.3-1.5) [
         <a href="#rid68">
          68
         </a>
         ]. However, discontinuation of treatment due to adverse effects was more than twice as large with active treatment than placebo (relative risk 2.4, 95% CI 1.7-3.4).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A network meta-analysis of 33 trials (n &gt;10,000 patients) evaluated the efficacy and tolerability of add-on antipsychotics by using results from direct comparisons between the drugs (in head-to-head trials), as well as indirectly comparing drugs through their relative effect with a common comparator (typically placebo) [
         <a href="#rid58">
          58
         </a>
         ]. The primary findings included the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The probability of response was greater with each antipsychotic (except
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         ) than placebo, and the probability was greatest with
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         (odds ratio 1.8, 95% CI 1.5-2.2) and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         (odds ratio 2.2, 95% CI 1.4-3.4).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The probability of response with
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         exceeded that for
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Discontinuation of treatment due to adverse effects was generally more likely with each antipsychotic than placebo. However, the likelihood of discontinuation among patients treated with
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         and placebo was comparable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional information about the efficacy of second-generation antipsychotics for treatment-resistant depression, including patients with a minimal response to the initial antidepressant, as well as information about safety issues (eg, metabolic syndrome and tardive dyskinesia) and the administration and side effects of these drugs  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 6
         </a>
         ), is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14688.html" rel="external">
          "Unipolar depression in adults: Treatment with second-generation antipsychotics"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy of
         </strong>
         <strong>
          lithium
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         augmentation has been used for treatment-resistant depression since the 1960s [
         <a href="#rid69">
          69
         </a>
         ], and multiple studies have subsequently demonstrated its efficacy [
         <a href="#rid42">
          42
         </a>
         ]. As an example, a meta-analysis of nine randomized trials (237 patients) compared adjunctive lithium with placebo and found that response was superior with lithium [
         <a href="#rid70">
          70
         </a>
         ]. In addition, subgroup analyses found that lithium was efficacious for augmenting either first-generation antidepressants (eg, tricyclics) or second-generation antidepressants (eg, SSRIs). Augmentation with lithium is consistent with multiple practice guidelines [
         <a href="#rid9">
          9,10,13,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another possible benefit of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is reduced risk of suicide. (See
         <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">
          "Suicidal ideation and behavior in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nevertheless, augmentation with drugs other than
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         may be preferred due to the risk of toxicity, the need to monitor serum concentrations, and adverse effects. Additional information about using lithium in treatment-resistant depression, including its dose, safety issues, and side effects, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13506.html" rel="external">
          "Unipolar depression in adults: Treatment with lithium"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1878663780">
         <span class="h5">
          Patients who prioritize tolerability
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who prioritize tolerability and avoiding adverse effects, we suggest augmentation with a second antidepressant from a different class as first-step treatment. If patients do not respond to a second antidepressant, we suggest augmentation with thyroid hormone (typically triiodothyronine). However, it is reasonable to first augment with triiodothyronine. Augmentation with another antidepressant or triiodothyronine is consistent with practice guidelines [
         <a href="#rid10">
          10,13,23
         </a>
         ].
        </p>
        <p>
         For resistant depression in patients who prioritize tolerability, the rationale for using a second antidepressant or thyroid hormone is that their adverse effects appear to be less, compared with other drugs that are commonly used for augmentation, such as second-generation antipsychotics and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         . However, the efficacy of a second antidepressant or thyroid hormone is less well established, and it is thus reasonable to augment with a second-generation antipsychotic or lithium instead.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          A second antidepressant
         </strong>
         – Depressive syndromes that respond incompletely to antidepressant monotherapy are often treated by adding a second antidepressant from a different class. However, certain antidepressant combinations should be avoided; as an example, an MAOI plus an SSRI, a serotonin-norepinephrine reuptake inhibitor (SNRI), a serotonin modulator, an atypical antidepressant, or a tricyclic can cause the serotonin syndrome or a hypertensive crisis [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">
          "Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Specific interactions between antidepressants may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The evidence suggests that combining two antidepressants is generally limited:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A meta-analysis of 20 randomized trials compared antidepressant combinations with antidepressant monotherapy in patients with depressive disorders that did not respond to initial treatment (n &gt;4500) [
         <a href="#rid71">
          71
         </a>
         ]. Improvement was greater with combination therapy, and withdrawal from treatment due to adverse effects appeared to be comparable for the two groups. However, the clinical advantage of combination therapy was small.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The results suggested that it is preferable to combine a monoamine reuptake inhibitor (SSRI, SNRI, or tricyclic antidepressant) with mianserin,
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         . In addition, antidepressant combinations that included
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         were superior to monotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 10-week, open-label randomized trial compared add-on
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         with add-on
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         in patients (n = 104) who did not respond to initial treatment with
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         [
         <a href="#rid72">
          72
         </a>
         ]. Citalopram was titrated up to 30 mg/day and target lithium serum concentrations were 0.6 to 0.8 mEq/L (0.6 to 0.8 mmol/L). Remission occurred in more patients who received adjunctive citalopram than lithium (40 versus 21 percent). Tolerability was not systematically assessed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional information about the use and efficacy of antidepressant combinations is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14671.html" rel="external">
          "Unipolar depression in adults: Treatment with antidepressant combinations", section on 'Treatment resistant depression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroid hormone
         </strong>
         – Thyroid hormone (eg, triiodothyronine) has been used as augmentation for treatment-resistant depression since the 1960s [
         <a href="#rid73">
          73
         </a>
         ], and subsequent studies have provided low-quality evidence supporting its efficacy. As an example, a meta-analysis of four randomized trials (95 depressed patients unresponsive to a tricyclic) compared adjunctive triiodothyronine (T3) to a control condition (either adjunctive placebo or thyroxine [T4]) [
         <a href="#rid51">
          51
         </a>
         ]. Although the clinical benefit of T3 was moderately large, and response (reduction of baseline depressive symptoms ≥50 percent) occurred in 53 percent more patients who received T3, the difference in the frequency of response between T3 and the control condition was not statistically significant (relative risk 1.53, 95% CI 0.70-3.35). In addition, it is not clear whether T3 augmentation is efficacious with antidepressants other than tricyclics [
         <a href="#rid74">
          74,75
         </a>
         ]. The efficacy, dose, safety issues, and side effects of thyroid hormone in treatment-resistant depression are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15722.html" rel="external">
          "Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13506.html" rel="external">
          "Unipolar depression in adults: Treatment with lithium", section on 'Triiodothyronine (T3)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         A reasonable alternative to a second antidepressant or thyroid hormone, particularly in patients with either cognitive impairment secondary to depression or comorbid attention-deficit hyperactivity disorder, is augmentation with stimulants. (See
         <a class="medical medical_review" href="/z/d/html/14676.html" rel="external">
          "Unipolar major depression in adults: Augmentation of antidepressants with stimulants and stimulant-like drugs"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H237522587">
         <span class="h3">
          Psychotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with unipolar major depression who receive an antidepressant as initial treatment and do not improve sufficiently, augmentation with psychotherapy is often beneficial and is consistent with practice guidelines [
         <a href="#rid4">
          4,8,10,11,23,76-79
         </a>
         ]. As an example:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of six randomized trials compared antidepressants plus add-on psychotherapy with antidepressants alone in 635 patients with treatment-resistant depression [
         <a href="#rid80">
          80
         </a>
         ]. Remission was nearly twice as likely with adjunctive psychotherapy (relative risk 1.9, 95% CI 1.5-2.5), and discontinuation of treatment was comparable for the two groups. Heterogeneity across studies was small to moderate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent meta-analysis of 20 randomized trials compared antidepressants plus add-on psychotherapy with antidepressants alone in nearly 3000 patients [
         <a href="#rid81">
          81
         </a>
         ]. The primary findings included the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Improvement was greater with adjunctive psychotherapy and the clinical benefit was small to moderate. However, heterogeneity across studies was moderate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The efficacy of specific psychotherapies, including CBT, interpersonal psychotherapy, and mindfulness-based cognitive therapy (MBCT), appeared to be comparable.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Greater baseline severity (intensity) of depressive symptoms was associated with greater improvement.
        </p>
        <p>
        </p>
        <p>
         However, treatment-resistant patients may decline psychotherapy despite its demonstrated benefits [
         <a href="#rid18">
          18
         </a>
         ]. In addition, psychotherapy may not be available.
        </p>
        <p>
         The specific choice of an adjunctive psychotherapy is usually based upon availability and patient preference because few head-to-head randomized trials have compared different psychotherapies in treatment-resistant depression. In addition, randomized trials in patients who present for initial treatment of depression indicate that there is no compelling evidence that one psychotherapy is superior to the rest. (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         .)
        </p>
        <p>
         Specific psychotherapies that have demonstrated efficacy for treatment-resistant depression include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cognitive-behavioral therapy
         </strong>
         – The most widely studied and utilized add-on psychotherapy for treatment-resistant depression is CBT. Meta-analyses of randomized trials indicate that adding CBT to pharmacotherapy provides a small to moderate clinical benefit [
         <a href="#rid81">
          81
         </a>
         ]. As an example, a meta-analysis of three randomized trials compared antidepressants plus add-on CBT with antidepressants alone in 522 patients who did not respond to antidepressants [
         <a href="#rid80">
          80
         </a>
         ]. Improvement was greater with adjunctive CBT, and the clinical effect was small to moderate. Results from the specific trials indicated that adjunctive CBT led to remission in 30 to 40 percent of patients [
         <a href="#rid82">
          82,83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The principles of CBT are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14612.html" rel="external">
          "Overview of psychotherapies", section on 'Cognitive and behavioral therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interpersonal psychotherapy
         </strong>
         – Evidence supporting add-on interpersonal psychotherapy with pharmacotherapy for treatment-resistant depression includes a meta-analysis of three randomized trials in patients who did not respond to pharmacotherapy (n = 233) [
         <a href="#rid81">
          81
         </a>
         ]. Improvement was greater in those treated with add-on interpersonal psychotherapy, and the clinical effect was small to moderate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an example, a four month trial enrolled patients (n = 64) who had not responded to an average of three antidepressants and were acutely depressed on average for approximately 26 months, and randomized them to an intervention consisting of interpersonal psychotherapy, occupational therapy, and pharmacotherapy or to treatment as usual (pharmacotherapy and/or psychotherapy) [
         <a href="#rid84">
          84
         </a>
         ]. Remission occurred in more patients who received interpersonal psychotherapy (35 versus 13 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         General information about interpersonal psychotherapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15675.html" rel="external">
          "Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14680.html" rel="external">
          "Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mindfulness-based cognitive therapy
         </strong>
         – Multiple randomized trials indicate that adjunctive MBCT can help patients with treatment-resistant depression. A meta-analysis of four trials in 325 patients who had not responded to pharmacotherapy compared ongoing pharmacotherapy plus add-on MBCT with pharmacotherapy alone [
         <a href="#rid81">
          81
         </a>
         ]. Improvement was greater with adjunctive MBCT, and the clinical benefit was moderate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         General information about MBCT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14682.html" rel="external">
          "Unipolar major depression: Treatment with mindfulness-based cognitive therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychodynamic psychotherapy
         </strong>
         – Psychodynamic psychotherapy has also demonstrated efficacy for treatment-resistant unipolar major depression [
         <a href="#rid85">
          85
         </a>
         ]. A 20-week randomized trial (n = 60 patients) compared ongoing pharmacotherapy plus weekly add-on psychodynamic psychotherapy with usual care consisting of pharmacotherapy and/or psychotherapy (eg, CBT) [
         <a href="#rid86">
          86
         </a>
         ]. Remission occurred in more patients who received add-on psychodynamic psychotherapy than usual care (36 versus 4 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The principles and administration of psychodynamic psychotherapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14689.html" rel="external">
          "Unipolar depression in adults: Psychodynamic psychotherapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other psychotherapies that are suitable for add-on treatment in patients with resistant depression include behavioral activation, family and couples therapy, problem solving therapy, and supportive psychotherapy. Each of these are discussed separately in UpToDate.
        </p>
        <p class="headingAnchor" id="H4008149457">
         <span class="h3">
          Transcranial magnetic stimulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with major depression that does not respond to initial treatment with an antidepressant, multiple randomized trials indicate that augmentation with TMS can be effective. As an example, a pooled analysis of six randomized trials compared active TMS with sham TMS as augmentation in patients (n = 230) with treatment-resistant depression who continued their antidepressant drugs [
         <a href="#rid87">
          87
         </a>
         ]. Patients received 10 to 30 sessions of high frequency, left surface cortical TMS. Response (eg, reduction of baseline symptoms ≥50 percent) occurred in more patients who received active than sham TMS (47 versus 22 percent). Augmentation with TMS is consistent with practice guidelines [
         <a href="#rid9">
          9,11,88
         </a>
         ].
        </p>
        <p>
         However, patients who respond to acute TMS generally require continuation and maintenance treatment with antidepressants, psychotherapy, or both. It is not known if maintenance treatment with TMS for unipolar major depression is beneficial. The efficacy of maintenance treatment with antidepressants, psychotherapy, or TMS are discussed separately, as is the technique for performing TMS. (See
         <a class="medical medical_review" href="/z/d/html/14674.html" rel="external">
          "Unipolar depression in adults: Continuation and maintenance treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14641.html" rel="external">
          "Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Maintenance TMS'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113603.html" rel="external">
          "Unipolar major depression: Administering transcranial magnetic stimulation (TMS)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8047894">
         <span class="h2">
          Next step treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For resistant, mild to moderate depression that does not respond to augmentation interventions, we suggest switching to a different treatment. Standard options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A different antidepressant
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychotherapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TMS
        </p>
        <p>
        </p>
        <p>
         The choice between these three options is generally based upon availability and patient preference because there is no compelling evidence that one is superior to the others for acute outcomes. Most patients switch antidepressants because this option is readily accessible and often preferred. In addition, patients with unipolar depression who do not respond to initial treatment with either pharmacotherapy or psychotherapy may respond to switching to the other modality. (See
         <a class="local">
          'Psychotherapy'
         </a>
         below.)
        </p>
        <p>
         Other factors may determine the choice when switching treatments. As an example, patients acutely ill with unipolar major depression who improve with pharmacotherapy and subsequently discontinue it appear to be at greater risk for relapse than patients who improve with and discontinue psychotherapy (eg, CBT). In addition, maintenance treatment with antidepressants or psychotherapy can forestall relapse. Although maintenance treatment with TMS for unipolar major depression is common, its efficacy has not been demonstrated in randomized trials. (See
         <a class="medical medical_review" href="/z/d/html/14674.html" rel="external">
          "Unipolar depression in adults: Continuation and maintenance treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14641.html" rel="external">
          "Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Maintenance TMS'
         </a>
         .)
        </p>
        <p>
         Patients with treatment-resistant depression who switch to a different treatment may also benefit from supplementary interventions such as exercise. (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4496258">
         <span class="h3">
          Antidepressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with major depression who are resistant to treatment with an SSRI at first presentation and are switching antidepressants, many options are available  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 7
         </a>
         ). The most commonly studied antidepressants are as follows, and are presented in our general order of preference based upon the number and quality of randomized trials that studied each option, as well as safety issues, side effect profiles  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 8
         </a>
         ), potential for drug-drug interactions, and ease of use  (
         <a class="graphic graphic_algorithm graphicRef131935" href="/z/d/graphic/131935.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid1">
          1,47,89
         </a>
         ]. Other factors to consider in changing antidepressants include treatment history, patient preference, cost, and comorbid general medical conditions. Patients with seizure disorders should avoid
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         , patients with obesity should avoid
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         , and patients with cardiovascular disease should avoid tricyclics and MAOIs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serotonin-norepinephrine reuptake inhibitors
         </strong>
         – For patients with resistant depression who are switching antidepressants, we generally choose the SNRI
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         extended release because it has been widely studied. However, other SNRIs are reasonable alternatives.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Multiple trials support switching to
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         in resistant depression [
         <a href="#rid89">
          89
         </a>
         ]. As an example, a pooled analysis of three randomized trials, in patients with major depression who did not respond sufficiently to initial treatment with an SSRI (n = 3375), compared switching to venlafaxine with switching to a different SSRI [
         <a href="#rid90">
          90
         </a>
         ]. Remission occurred in more patients who received venlafaxine (54 versus 45 percent), and the number of dropouts because of side effects was comparable for the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pharmacology, administration, and side effects of
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         and other SNRIs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">
          "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical antidepressants
         </strong>
         – For depressed patients who are resistant to initial treatment with an SSRI, randomized trials indicate that remission is statistically comparable for patients who switch to either an atypical antidepressant (eg,
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         or
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         ) or a different SSRI. Clinicians may expect that an atypical antidepressant will lead to remission in roughly 20 to 35 percent of patients:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The STAR*D study included a 14-week trial that compared
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         sustained release (mean dose 283 mg per day) with
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         (mean dose 136 mg per day) in 477 treatment-resistant patients; medications were administered on an open-label basis and assessment of outcome was blinded [
         <a href="#rid91">
          91
         </a>
         ]. Remission was comparable for bupropion and sertraline (21 and 18 percent), as was tolerability.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An eight-week trial in 100 treatment-resistant patients found that remission with either
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         (45 mg per day) or
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         (20 mg per day) was comparable (36 and 47 percent), as was tolerability [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another atypical antidepressant option is
         <a class="drug drug_general" data-topicid="139442" href="/z/d/drug information/139442.html" rel="external">
          dextromethorphan-bupropion
         </a>
         . Although this medication is approved for treatment of unipolar major depression, and may have greater benefit than
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         alone, no trials have compared the drug with other antidepressants.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pharmacology, administration, and side effects of atypical antidepressants are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/85816.html" rel="external">
          "Atypical antidepressants: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tricyclic antidepressants
         </strong>
         – Tricyclic antidepressants are fourth- or fifth-line drugs for treatment of depression due to their greater safety hazards (eg, cardiotoxicity and potential lethality with overdose) and less favorable side effect profiles [
         <a href="#rid92">
          92
         </a>
         ]. However, for patients with treatment-resistant depression, the efficacy and tolerability of tricyclics may be comparable to other antidepressants and SSRIs, and clinicians may expect that a tricyclic will lead to remission in 20 to 70 percent of patients [
         <a href="#rid93">
          93,94
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the STAR*D study, an open-label, 14-week randomized trial (n = 235) compared switching to
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         (mean dose 97 mg per day) with switching to
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         (mean dose 42 mg per day) and found that remission was statistically comparable (20 and 12 percent), as was tolerability [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In another trial, patients were initially treated with
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         ; those who did not remit (n = 112) were randomly assigned to switch to
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         or to add-on treatment with
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         30 mg/day [
         <a href="#rid40">
          40
         </a>
         ]. Imipramine was dosed to achieve a combined serum imipramine plus
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         concentration of 175 to 300 ng/mL. After 10 weeks, remission occurred in more patients who switched to imipramine than those who added mirtazapine (71 versus 39 percent). However, all-cause discontinuation was two-fold greater with imipramine (9 and 4 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pharmacology, administration, and side effects of tricyclics are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monoamine oxidase inhibitors
         </strong>
         – MAOIs are seldom prescribed because of potentially lethal drug-drug and drug-food interactions, as well as adverse effects and the danger that MAOIs pose in overdoses [
         <a href="#rid92">
          92,96
         </a>
         ]. Nevertheless, switching to an MAOI may be beneficial for patients with major depression that is resistant to other drug classes  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid90">
          90,97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence that supports switching to MAOIs includes a network meta-analysis of 52 randomized trials that compared an MAOI to another antidepressant and/or placebo in patients with depressive disorders (n &gt;6400) [
         <a href="#rid98">
          98
         </a>
         ]. The meta-analysis used results from direct comparisons between drugs, as well as indirect comparisons of the drugs through their relative effect with a common comparator (typically placebo). The efficacy (response rate) and acceptability (all-cause discontinuation) of the MAOIs
         <a class="drug drug_general" data-topicid="10059" href="/z/d/drug information/10059.html" rel="external">
          moclobemide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">
          phenelzine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9883" href="/z/d/drug information/9883.html" rel="external">
          selegiline
         </a>
         , and
         <a class="drug drug_general" data-topicid="10012" href="/z/d/drug information/10012.html" rel="external">
          tranylcypromine
         </a>
         were comparable to the three SSRIs and six tricyclics that were included. Among the 13 antidepressants that were studied, the drug with the greatest efficacy was phenelzine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pharmacology, administration, dietary restrictions  (
         <a class="graphic graphic_table graphicRef80345" href="/z/d/graphic/80345.html" rel="external">
          table 9
         </a>
         ), and side effects of MAOIs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">
          "Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In addition, it is reasonable to switch patients from an ineffective SSRI to a serotonin modulator such as
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         and
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86265.html" rel="external">
          "Serotonin modulators: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
         In switching from initial treatment with an SSRI to another antidepressant, is reasonable to use the drugs listed above in a different sequence, or to switch to a different SSRI at any point in the sequence [
         <a href="#rid90">
          90
         </a>
         ]. In the few head-to-head studies that have compared different antidepressants for treatment-resistant depression, efficacy is often comparable [
         <a href="#rid1">
          1
         </a>
         ]. As an example, an eight-week randomized trial (n = 105 patients) compared switching to either
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         extended release 225 mg per day or
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         45 mg per day and found that remission was comparable (42 and 36 percent) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         We typically use a drug from a different class when switching antidepressants for treatment-resistant depression, rather than switching to an antidepressant within the same class, especially if there are problematic, class-wide adverse effects (eg, sexual dysfunction, which can occur with different SSRIs) [
         <a href="#rid17">
          17
         </a>
         ]. Evidence supporting a switch to an antidepressant in a different class includes a pooled analysis of four randomized trials involving patients with unipolar major depression who were resistant to initial treatment with an SSRI (n = 1496), and were switched either to a non-SSRI antidepressant (
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         ,
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         ) or to a different SSRI [
         <a href="#rid89">
          89
         </a>
         ]. Remission was statistically greater in patients who switched to a different drug class (28 versus 24 percent); in addition, discontinuation due to side effects was comparable for the two groups. However, given the modest difference in remission (4 percent), switching from one SSRI to another is reasonable [
         <a href="#rid99">
          99,100
         </a>
         ].
        </p>
        <p>
         For treatment-resistant patients who are switching antidepressants, we generally cross-taper, that is, taper and discontinue the failed medication over one to two weeks while another antidepressant is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease. As an example,
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         extended release 225 mg per day is decreased by 37.5 to 75 mg per day every one to three days. Implementing switches is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1716.html" rel="external">
          "Switching antidepressant medications in adults", section on 'Switching antidepressant medications'
         </a>
         .)
        </p>
        <p>
         If cross-tapering is used for antidepressant switches, clinicians should be aware of overlapping side effect profiles  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 8
         </a>
         ), as well as potential drug-drug interactions such as the serotonin syndrome (see
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         ) [
         <a href="#rid101">
          101
         </a>
         ]. Specific interactions between antidepressants may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p>
         Preliminary studies have examined the clinical utility of selecting an antidepressant based upon tests that assess genes involved in a drug’s pharmacokinetics and pharmacodynamics [
         <a href="#rid102">
          102,103
         </a>
         ]. However, using these pharmacogenetic tests is not standard practice because they do not consistently lead to clinically meaningful outcomes for treating depression [
         <a href="#rid104">
          104
         </a>
         ]. As an example, a 24-week, open-label randomized trial in patients with treatment-resistant unipolar major depression (n = 1944) compared pharmacogenetic testing with usual care for choosing a new antidepressant [
         <a href="#rid105">
          105
         </a>
         ]. Although remission at week 12 was greater with testing-guided care than usual care, the clinical effect was small and at week 24, remission in the genomic testing and control groups was nearly identical (17 and 16 percent).
        </p>
        <p>
         Although some studies suggest that switching antidepressants may not be effective for treatment-resistant depression, the methods used are problematic. As an example, a meta-analysis of eight randomized trials, which enrolled patients (n = 1627) who did not respond to an antidepressant, found that switching antidepressants was no better than continuing the initial antidepressant [
         <a href="#rid106">
          106
         </a>
         ]. However, the duration of treatment with the initial antidepressant was typically inadequate, such that the initial treatment trial lasted only two weeks in 29 percent of the patients and only four weeks in another 38 percent. The duration of an adequate treatment trial with an antidepressant is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H947618">
         <span class="h3">
          Psychotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For treatment-resistant major depression, switching to psychotherapy is a reasonable option for patients who prefer it, and is consistent with practice guidelines [
         <a href="#rid10">
          10,11,23,52,76,79
         </a>
         ]. Evidence supporting a switch to psychotherapy includes a 12-week trial that enrolled 122 patients who did not respond to or tolerate
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         and randomly assigned them to cognitive therapy or to a different antidepressant (
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         ,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         , or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         ) [
         <a href="#rid107">
          107
         </a>
         ]. Remission was comparable for cognitive therapy and pharmacotherapy (25 and 28 percent of patients), as was discontinuation of treatment due to side effects (17 and 27 percent). Acceptability of cognitive therapy was greater among patients with more education (eg, college graduates) and a family history of mood disorders [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         In addition, another trial found that all-cause discontinuation of treatment occurred in fewer patients who received psychotherapy than pharmacotherapy [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
         Although switching from an antidepressant to psychotherapy can be effective for treatment-resistant depression, many patients decline this option [
         <a href="#rid18">
          18
         </a>
         ]. In addition, psychotherapy is often not available.
        </p>
        <p class="headingAnchor" id="H4064194433">
         <span class="h3">
          Transcranial magnetic stimulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with resistant major depression who decide to switch treatment, another reasonable option is repetitive TMS. Switching to TMS is consistent with practice guidelines [
         <a href="#rid9">
          9,11,88
         </a>
         ].
        </p>
        <p>
         Multiple randomized trials that compared TMS with sham treatment (placebo) as monotherapy indicate that TMS can be efficacious for acute treatment-resistant depression. As an example, a meta-analysis of 43 randomized trials compared high-frequency left TMS with sham TMS in patients with treatment-resistant depression (n &gt;1900). Response was four times more likely to occur with active TMS (odds ratio 4, 95% CI 2-5) [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
         However, patients who respond to acute TMS generally require continuation and maintenance treatment with antidepressants, psychotherapy, or both. It is not known if maintenance treatment with TMS for unipolar major depression is beneficial. The efficacy of maintenance treatment with antidepressants, psychotherapy, or TMS are discussed separately, as is the technique for performing TMS. (See
         <a class="medical medical_review" href="/z/d/html/14674.html" rel="external">
          "Unipolar depression in adults: Continuation and maintenance treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14641.html" rel="external">
          "Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Maintenance TMS'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113603.html" rel="external">
          "Unipolar major depression: Administering transcranial magnetic stimulation (TMS)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8047542">
         <span class="h1">
          SEVERE DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Determining the severity of a depressive syndrome has not been standardized. The three paragraphs immediately below describe different means of establishing severity, in descending order of preference.
        </p>
        <p>
         Severe major depression is indicated by a score ≥20 points on the self-report Patient Health Questionnaire – Nine Item (PHQ-9)  (
         <a class="graphic graphic_table graphicRef59307" href="/z/d/graphic/59307.html" rel="external">
          table 4
         </a>
         ). The PHQ-9 is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14860.html" rel="external">
          "Using scales to monitor symptoms and treat depression (measurement based care)", section on 'Patient Health Questionnaire - Nine Item'
         </a>
         .)
        </p>
        <p>
         Alternatively, one study classified episodes of major depression as severe in those individuals who had eight or nine of the nine symptoms that define major depression  (
         <a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. This is consistent with the approach used in the DSM-5-TR [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Many studies have assessed severity of depression using clinician administered instruments, such as the Hamilton Rating Scale for Depression  (
         <a class="graphic graphic_table graphicRef72220" href="/z/d/graphic/72220.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ] or Montgomery-Asberg Depression Rating Scale  (
         <a class="graphic graphic_figure graphicRef62945 graphicRef67951 graphicRef81162" href="/z/d/graphic/62945.html" rel="external">
          figure 1A-C
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. However, these rating scales are generally not part of standard care.
        </p>
        <p>
         Patients who are severely ill with major depression often report suicidal ideation and behavior, typically demonstrate obvious impairment of functioning, and are more likely to develop complications such as psychotic features (eg, delusions and/or hallucinations) and catatonia. These patients should be referred to a psychiatrist for management and frequently require hospitalization [
         <a href="#rid9">
          9,10,19,20
         </a>
         ]. Treatment of major depression with psychotic features or catatonia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">
          "Unipolar major depression with psychotic features: Acute treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15869.html" rel="external">
          "Catatonia: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1520811914">
         <span class="h2">
          Initial approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with treatment-resistant, severe, nonpsychotic, noncatatonic unipolar major depression, we suggest initially using
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         rather than electroconvulsive therapy (ECT), based upon efficacy, safety, adverse effects, and patient preferences [
         <a href="#rid42">
          42,52,110-113
         </a>
         ]. However, a reasonable alternative is
         <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">
          esketamine
         </a>
         (S-ketamine), which is one of the two enantiomers that constitute racemic ketamine [
         <a href="#rid114">
          114-116
         </a>
         ]. In addition, ECT is well-established as a highly effective intervention for treatment resistance and is thus a reasonable alternative to ketamine/esketamine.
        </p>
        <p>
         As part of shared decision making, clinicians and patients should review the following aspects of treatment:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Although the relative benefits of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and ECT for severe, nonpsychotic, noncatatonic resistant depression vary across different randomized trials, the best evidence suggests that ketamine is superior.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Randomized trials that favor each treatment are as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ketamine/
         <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">
          esketamine
         </a>
         – Studies that indicate
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         is superior to ECT include an open-label, three-week trial that compared ketamine with ECT in nonpsychotic 365 patients (primarily outpatients) [
         <a href="#rid117">
          117
         </a>
         ]. Intravenous ketamine was administered two times per week at a dose of 0.5 mg/kg over 40 minutes. ECT was administered three times per week, initially using right unilateral ultrabrief pulse at six times the seizure threshold; during the trial, 39 percent of patients were switched to bilateral placement, which many experts regard as the standard of care [
         <a href="#rid118">
          118
         </a>
         ]. Response (reduction of symptoms ≥50 percent) occurred in more patients who received ketamine than ECT (55 versus 41 percent) [
         <a href="#rid117">
          117
         </a>
         ]. During the six-month follow-up of patients who responded, relapse in the ketamine and ECT groups occurred in 35 and 56 percent. However, some patients who did not respond to nine ECT treatments may have responded to a few (eg, three) more treatments.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Indirect evidence regarding the benefit of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         /
         <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">
          esketamine
         </a>
         includes a 32-week, open-label randomized trial that compared esketamine with
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         extended-release (XR) in patients with treatment-resistant major depression (n = 676) [
         <a href="#rid119">
          119
         </a>
         ]. Study treatments were added to ongoing treatment with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor. Esketamine was flexibly dosed at 28, 56 or 84 mg, and administered twice weekly during weeks 1 to 4, and weekly or every two weeks during weeks 5 to 32. Quetiapine XR was flexibly dosed at 150 to 300 mg/day. More patients remitted with esketamine than quetiapine XR (49 versus 33 percent). In addition, discontinuation of treatment due to adverse events occurred in nearly three times as many patients treated with quetiapine XR than esketamine (11 and 4 percent), which contributed to the differences in remission.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ECT – Prior open-label trials suggest that ECT is superior to
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         [
         <a href="#rid120">
          120
         </a>
         ]. As an example, a meta-analysis of three trials compared ECT with ketamine in 229 patients, some of whom had psychotic features [
         <a href="#rid121">
          121
         </a>
         ]. ECT was administered a total of 3 to 12 times with either right unilateral or bilateral placement; ketamine was infused 3 to 12 times at a dose of 0.5 mg/kg. Response was modestly greater with ECT (relative risk 1.3, 95% CI 1.1-1.5). Despite the greater benefit with ECT, the relatively small advantage led the investigators to recommend that clinicians use ketamine before ECT, presumably because other aspects of treatment favor ketamine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suicidal ideation and behavior
         </strong>
         – Both
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and ECT can be particularly helpful for patients with refractory, active suicidal ideation that includes a plan and intent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Time to onset of response
         </strong>
         – A meta-analysis of two trials (total n = 139) found that the number of treatment sessions required to achieve response was comparable with
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and ECT [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety
         </strong>
         – Although
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         is approved as a general anesthetic, subanesthetic doses are administered for resistant depression. By contrast, ECT requires brief general anesthesia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ketamine
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Substance use disorder –
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         may be misused as an intoxicant/euphoriant and can lead to diversion and physiologic and psychological dependence [
         <a href="#rid122">
          122,123
         </a>
         ]. Thus, depressed patients with comorbid substance use disorders are typically not candidates for ketamine [
         <a href="#rid124">
          124
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Dissociation and psychotomimetic effects – Potential adverse effects of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         include dissociative and psychotomimetic symptoms. As an example, an open-label, randomized trial in 365 patients found that dissociative symptoms were greater in patients who received ketamine than ECT [
         <a href="#rid117">
          117
         </a>
         ]. In addition, a prior meta-analysis of three trials (total n = 230) found that the risk of dissociation was six times greater with ketamine than ECT [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ECT
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Memory – ECT can cause memory impairment that may persist for at least six months. In a three-week, open-label randomized trial, multiple measures of memory at the end of treatment were worse with ECT than
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         [
         <a href="#rid117">
          117
         </a>
         ]. At the six-month follow-up of responders, clinician-administered measures showed that ECT related memory impairment resolved within one to six months, but patient self-report measures indicated that memory remained worse among those who received ECT.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Musculoskeletal effects – A three-week, open-label, randomized trial (n = 365 patients) found that muscle pain or weakness with ECT or
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         occurred in 5.3 and 0.5 percent [
         <a href="#rid117">
          117
         </a>
         ]. In addition, other trials found that musculoskeletal pain occurred more often with ECT than ketamine [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient preferences
         </strong>
         – Patients may typically prefer
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         over ECT. In a trial that randomly assigned 403 patients to either ketamine or ECT, 4 patients in the ketamine group withdrew from the study before starting their assigned treatment, compared with 31 in the ECT group [
         <a href="#rid117">
          117
         </a>
         ]. Ketamine may be more acceptable to patients because it carries less stigma and causes fewer problems with memory.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patient preferences may also affect the choice between
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and
         <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">
          esketamine
         </a>
         . Most studies of ketamine in academic centers have administered it intravenously, but it is also available in intramuscular, intranasal, oral, subcutaneous, and sublingual formulations. In addition, the drug is available in free-standing outpatient clinics. By contrast, intranasal esketamine is available in the United States only through a Risk Evaluation and Mitigation Strategy program, in which the drug is sold to certified medical offices for specific patients who are enrolled in a registry. Patients self-administer the drug in the office and are then monitored for at least two hours by clinicians in the office. Esketamine is kept under lock and key and is not allowed to leave the office.
        </p>
        <p>
        </p>
        <p>
         Information about prescribing intravenous
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         according to best practices is discussed in the Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p>
         Additional information about
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and ECT, including their efficacy, safety, and adverse effects, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/119992.html" rel="external">
          "Ketamine and esketamine for treating unipolar depression in adults: Administration, efficacy, and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1711.html" rel="external">
          "Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">
          "Overview of electroconvulsive therapy (ECT) for adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H180709707">
         <span class="h2">
          Next step treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe, treatment-resistant, nonpsychotic, noncatatonic unipolar major depression who choose
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         for initial management may not respond. For these patients, next step treatment is ECT, which is generally regarded as more efficacious than other treatments [
         <a href="#rid125">
          125-127
         </a>
         ]. The efficacy of ECT extends to patients with persistent, serious suicidal ideation, and those with severe weight loss, malnutrition, or dehydration secondary to refusal of food and fluids [
         <a href="#rid88">
          88,125,128-130
         </a>
         ]. Using ECT is consistent with multiple treatment guidelines [
         <a href="#rid9">
          9,11,19-21,23,88
         </a>
         ].
        </p>
        <p>
         Meta-analyses of randomized trials indicate that ECT is superior to pharmacotherapy (other than
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ) for unipolar major depression [
         <a href="#rid131">
          131-133
         </a>
         ]. As an example, a meta-analysis of 18 trials (1144 patients) compared ECT with pharmacotherapy and found that ECT was more efficacious [
         <a href="#rid134">
          134
         </a>
         ]. In one open-label trial that compared ECT with
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         in 39 patients with treatment-resistant depression, response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received ECT than paroxetine (71 versus 28 percent) [
         <a href="#rid135">
          135
         </a>
         ].
        </p>
        <p>
         In addition, the efficacy of ECT is comparable or superior to other neuromodulation interventions for major depressive episodes, including repetitive transcranial magnetic stimulation (TMS) [
         <a href="#rid136">
          136-138
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A network meta-analysis of randomized trials evaluated the efficacy of nonsurgical neuromodulation interventions by pooling results from direct comparisons between the therapies in head to head trials, as well as indirectly comparing therapies through their relative effect with a common comparator (sham stimulation) [
         <a href="#rid109">
          109
         </a>
         ]. The probability of response was greatest with bitemporal ECT and high-dose right unilateral ECT, relative to repetitive TMS and transcranial direct current stimulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pooled analysis of seven randomized trials (either open-label or blinded rater) compared ECT (bilateral or unilateral) with repetitive TMS (applied over the left or right dorsolateral prefrontal cortex) in 275 patients with major depression [
         <a href="#rid139">
          139
         </a>
         ]. Remission occurred in more patients who received ECT than repetitive TMS (53 versus 32 percent). In addition, discontinuation of treatment for any reason was comparable for ECT and repetitive TMS (12 and 14 percent). However, cognitive impairment in specific domains (eg, verbal fluency and visual memory) may be greater with ECT [
         <a href="#rid139">
          139-141
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Nevertheless, ECT is associated with safety risks, adverse effects, logistical constraints, and patient refusal, and relapse rates following remission are high, especially in patients with treatment-resistant depression [
         <a href="#rid142">
          142,143
         </a>
         ]. An overview of ECT is discussed separately, as are indications for and efficacy of ECT in unipolar major depression, medical consultation for ECT, and the technique for performing ECT. (See
         <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">
          "Overview of electroconvulsive therapy (ECT) for adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1711.html" rel="external">
          "Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">
          "Medical evaluation for electroconvulsive therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">
          "Technique for performing electroconvulsive therapy (ECT) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1130830467">
         <span class="h2">
          Other options
         </span>
         <span class="headingEndMark">
          —
         </span>
         For treatment-resistant, severely depressed patients who do not respond to or who decline
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and ECT, we suggest antidepressants, as well as psychotherapy if it is feasible.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacotherapy
         </strong>
         – For these patients, it is not clear that one class of antidepressants  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 7
         </a>
         ) is superior to others. However, some evidence suggests that tricyclics may be preferred [
         <a href="#rid21">
          21
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A meta-analysis of 25 randomized trials compared tricyclics with SSRIs in 1377 hospitalized patients who were not selected for treatment resistance [
         <a href="#rid144">
          144
         </a>
         ]. Although tricyclics were more efficacious than SSRIs, the clinical difference was small, and heterogeneity across studies was significant. In addition, discontinuation of treatment occurred in more patients who received tricyclics than SSRIs (14 versus 9 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a subsequent trial, patients who were initially treated with
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         and did not remit (n = 112) were randomly assigned to switch to open-label
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         or add-on treatment with
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         30 mg/day [
         <a href="#rid40">
          40
         </a>
         ]. Imipramine was dosed to achieve a combined serum imipramine plus
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         concentration of 175 to 300 ng/mL. After 10 weeks, remission occurred in more patients who switched to imipramine than those who added mirtazapine (71 versus 39 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional information about choosing an antidepressant for treatment-resistant, severe depression is discussed elsewhere in this topic in the context of mild to moderate depression. (See
         <a class="local">
          'Antidepressants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other severely ill, treatment-resistant patients may benefit from augmentation with another medication, such as a second antidepressant. In one study, patients with a baseline score on the 17-item Hamilton Rating Scale for Depression  (
         <a class="graphic graphic_table graphicRef72220" href="/z/d/graphic/72220.html" rel="external">
          table 5
         </a>
         ) ≥24 were initially treated with
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         , which was dosed to achieve a combined serum imipramine plus
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         concentration of 175 to 300 ng/mL. Patients who did not remit (n = 104) were randomly assigned, on an open-label basis, to add-on either
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         titrated up to 30 mg/day or
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         dosed to achieve a serum concentration of 0.6 to 0.8 mEq/L (0.6 to 0.8 mmol/L) [
         <a href="#rid72">
          72
         </a>
         ]. After 10 weeks, remission occurred in more patients who received adjunctive citalopram than adjunctive lithium (40 versus 21 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional information about augmentation is discussed elsewhere in this topic, in the context of mild to moderate depression. (See
         <a class="local">
          'Initial approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For depression resistant to many courses (eg, seven) of pharmacotherapy, a rarely used regimen that may be indicated is the combination of a tricyclic antidepressant and an MAOI. This combination is a treatment of last resort due to potential life-threatening drug-drug interactions, including the serotonin syndrome and hypertensive crisis [
         <a href="#rid21">
          21,145,146
         </a>
         ]. Combining these two drug classes requires a thorough discussion of the risks and benefits, as well as careful monitoring. Generally, the MAOI is added after a failed trial of tricyclic monotherapy, rather than vice versa or simultaneous initiation of both drugs [
         <a href="#rid147">
          147
         </a>
         ]. In addition, the dose for each drug is comparable to the dose used for monotherapy  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 7
         </a>
         ). Drug-drug interactions (including the serotonin syndrome) between MAOIs and tricyclics may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate. Detailed information about the administration and safety of tricyclics and MAOIs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">
          "Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Low-quality evidence supporting the use of a tricyclic plus an MAOI includes a retrospective study of 62 cases [
         <a href="#rid147">
          147
         </a>
         ]. The tricyclics included
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         , and the MAOIs included
         <a class="drug drug_general" data-topicid="8991" href="/z/d/drug information/8991.html" rel="external">
          isocarboxazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">
          phenelzine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10012" href="/z/d/drug information/10012.html" rel="external">
          tranylcypromine
         </a>
         . The combination appeared to be effective and safe; serotonin syndrome occurred in one case and hypertension was not observed. Other adverse effects were consistent with those that may occur with monotherapy  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 8
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychotherapy
         </strong>
         – We typically include psychotherapy for severe episodes of major depression that are treatment resistant. Most hospitalized patients receive individual and/or group psychotherapy, provided that they are well enough to participate in therapy [
         <a href="#rid148">
          148
         </a>
         ]. Indirect evidence supporting the use of psychotherapy for severe episodes of treatment-resistant depression includes randomized trials in patients with mild to moderate episodes of treatment-resistant depression (see
         <a class="local">
          'Psychotherapy'
         </a>
         above). In addition, randomized trials indicate that patients who present for initial treatment of severe major depression can benefit from pharmacotherapy plus psychotherapy. (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment", section on 'Choosing a treatment regimen'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Only low-quality studies have evaluated psychotherapy in treatment-resistant, severe depression. As an example, two relatively small and old studies yielded conflicting results:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 12-week randomized trial compared cognitive-behavioral therapy (CBT) plus pharmacotherapy with pharmacotherapy alone in 20 patients hospitalized for chronic (duration ≥2 years) depression; improvement was comparable for the two groups [
         <a href="#rid149">
          149
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A prospective observational study included 174 patients with treatment-resistant depression who were hospitalized for four to seven months and treated with pharmacotherapy, CBT, milieu therapy, occupational therapy, and couples therapy, as well as ECT if indicated [
         <a href="#rid148">
          148
         </a>
         ]. Response (reduction of baseline symptoms ≥50 percent) occurred in 47 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vagus nerve stimulation
         </strong>
         – Another option that we generally do
         <strong>
          not
         </strong>
         prescribe is vagus nerve stimulation, which involves surgery to attach an electrode around one vagus nerve; the electrode is connected by a wire to a pulse generator implanted subcutaneously in the chest wall. There are no compelling data that indicate vagus nerve stimulation is efficacious for treatment-resistant unipolar major depression. A 10-week trial enrolled 222 patients who did not respond to pharmacotherapy (two to six regimens) and randomly assigned them to vagus nerve stimulation or sham treatment; response in the two groups was comparable (15 and 10 percent of patients) [
         <a href="#rid150">
          150
         </a>
         ]. Avoiding vagus nerve stimulation or limiting its use is consistent with practice guidelines from the American Psychiatric Association, the United Kingdom National Institute for Health and Care Excellence, and other groups [
         <a href="#rid9">
          9,19,20,151,152
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nevertheless, other clinicians do refer patients for vagus nerve stimulation, based upon prospective observational studies that suggest it may possibly help treatment-resistant depression [
         <a href="#rid153">
          153,154
         </a>
         ]. One proposed explanation for the negative randomized trial described immediately above is that several months may be required for the benefits of vagus nerve stimulation to manifest. The treatment is approved by the US Food and Drug Administration and the European Medicines Agency [
         <a href="#rid155">
          155,156
         </a>
         ]; in addition, prescribing the intervention is consistent with multiple treatment guidelines, including those issued by the Canadian Network for Mood and Anxiety Treatments and British Association for Psychopharmacology [
         <a href="#rid21">
          21,22,88,157
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional information about vagus nerve stimulation, including its efficacy, safety, and side effect profile, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16518.html" rel="external">
          "Unipolar depression in adults: Treatment with surgical approaches", section on 'Vagus nerve stimulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1994515286">
         <span class="h1">
          INVESTIGATIONAL TREATMENTS
         </span>
        </p>
        <p class="headingAnchor" id="H590048164">
         <span class="h2">
          Psilocybin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psilocybin is an investigational psychedelic drug that is synthesized or derived from a particular genus of mushrooms, and produces large effects on perception and consciousness (eg, hallucinations) [
         <a href="#rid158">
          158
         </a>
         ]. Four randomized trials in patients with treatment-resistant unipolar major depression, lasting 6 to 12 weeks, have each found that one or two doses of psilocybin (approximately 25 mg) plus supportive psychotherapy can be efficacious [
         <a href="#rid159">
          159-162
         </a>
         ]. The most common adverse effects of psilocybin were headache and nausea. However, suicidal ideation and behavior also occurred in one trial, and blinding to treatment with psychedelics is difficult. The use of psilocybin is usually accompanied by supportive preparatory and post drug “integrative” sessions but conceptualization of this as “drug-assisted psychotherapy” is controversial [
         <a href="#rid158">
          158,163-166
         </a>
         ].
        </p>
        <p>
         In the trials, most patients had a history of recurrent depression and had not responded to at least two antidepressants during the current depressive episode [
         <a href="#rid159">
          159-162
         </a>
         ]. Exclusion criteria included history of psychosis, serious suicide attempt, substance use disorder, and comorbid psychopathology that could interfere with the therapeutic alliance between the patient and study clinicians (eg, borderline personality disorder). Psilocybin was administered in a controlled setting along with psychological assistance that included preparation for ingesting psilocybin, support during the visits in which psilocybin was dispensed, and subsequent integration sessions to discuss the psilocybin experience. Treatment sessions in which psilocybin was administered lasted 4 to 10 hours.
        </p>
        <p>
         Other details of the methods and results from two relatively large, randomized trials are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A six-week trial compared a single dose of psilocybin (25 mg) with niacin (100 mg) in 104 patients [
         <a href="#rid162">
          162
         </a>
         ]. Improvement was greater with psilocybin than niacin as early as day 8, and persisted until day 43. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients with psilocybin than niacin (42 versus 11 percent). In addition, occupational, social, and family functioning improved more with active treatment, as did anxiety and quality of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse events occurred in more patients with psilocybin than niacin (76 versus 30 percent). Passive suicidal ideation in the psilocybin and niacin groups increased in one and five patients; no suicidal or nonsuicidal self-injurious behavior occurred.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another trial assigned 158 patients to one dose of psilocybin at 25 mg or 1 mg [
         <a href="#rid161">
          161
         </a>
         ]. Improvement was greater with 25 mg, and response occurred in twice as many patients with 25 mg than 1 mg at week 3 (37 and 18 percent) and at week 12 (20 and 10 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, serious adverse events that occurred included the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         By week 3, in the 25 mg group, suicidal ideation occurred in two patients and nonsuicidal self-injury occurred in two other patients; in the 1 mg group, there were no serious adverse events.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         After week 3 and up to week 12, in the 25 mg group, suicidal behavior occurred in three patients; in the 1 mg group, nonsuicidal self-injury occurred in one patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These adverse events occurred despite excluding patients with a significant risk of suicide at baseline from the trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other randomized trials have shown that psilocybin can be efficacious for depressive syndromes in patients with life-threatening cancer [
         <a href="#rid165">
          165,167,168
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The mechanism of action for psilocybin may involve its direct agonist effects on serotonin 2A receptors [
         <a href="#rid165">
          165
         </a>
         ]. Another hypothesis is that the drug disrupts circuits that underlie maladaptive thoughts of guilt and ruminations about one’s inadequacies [
         <a href="#rid163">
          163
         </a>
         ].
        </p>
        <p>
         We view psilocybin as an investigational intervention for treatment-resistant depression. Although psychiatrists in Australia can register to prescribe the drug, restricting use of psilocybin to registered clinical trials is consistent with practice guidelines [
         <a href="#rid165">
          165,169
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3990037870">
         <span class="h2">
          Nitrous oxide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         is a clinically available N-methyl-D-aspartate (NMDA) receptor antagonist akin to
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and a standard anesthetic drug that may perhaps help patients with treatment-resistant depression. A randomized trial compared adjunctive inspiratory nitrous oxide (50 percent nitrous oxide plus 50 percent oxygen) with placebo (50 percent nitrogen plus 50 percent oxygen) in patients with treatment-resistant depression who were receiving a stable treatment regimen (n = 20) [
         <a href="#rid170">
          170
         </a>
         ]. Study drugs were administered in a single session lasting one hour. Improvement of depression was greater with add-on nitrous oxide than placebo at 2 hours, 24 hours, and one-week posttreatment. However, nitrous oxide may be abused because of its intoxicating properties, and the longer term benefits and toxicity of nitrous oxide are unknown.
        </p>
        <p class="headingAnchor" id="H247090478">
         <span class="h2">
          Neuromodulation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Noninvasive neuromodulation
         </strong>
         – Investigational, noninvasive neuromodulation procedures, which use an electric current or magnetic field to stimulate the central nervous system, may perhaps be helpful for treatment-resistant depression [
         <a href="#rid171">
          171
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16519.html" rel="external">
          "Unipolar depression in adults: Overview of neuromodulation procedures", section on 'Noninvasive neuromodulation therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Invasive/surgical neuromodulation
         </strong>
         – Patients with severe, intractable, and incapacitating unipolar major depression, which does not respond to numerous (eg, 7 to 10) trials of standard therapies and has persisted for years (eg, ≥2 to 5), may be candidates for investigational neurosurgical interventions that lack high-quality efficacy data. The most widely studied surgical intervention is deep brain stimulation; a less common invasive approach is direct cortical stimulation. Invasive treatments should be pursued only at tertiary referral centers that are conducting research and providing rigorous oversight to ensure that the procedure is indicated. The efficacy, safety, and side effects of experimental invasive/surgical neuromodulation procedures are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16518.html" rel="external">
          "Unipolar depression in adults: Treatment with surgical approaches"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2846192401">
         <span class="h1">
          MAINTENANCE TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who remit from treatment-resistant depression typically require maintenance treatment. (See
         <a class="medical medical_review" href="/z/d/html/14674.html" rel="external">
          "Unipolar depression in adults: Continuation and maintenance treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1739287021">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">
          "Society guideline links: Depressive disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H364600">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15342.html" rel="external">
          "Patient education: Depression in adults (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/83813.html" rel="external">
          "Patient education: When you have depression and another health problem (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4868.html" rel="external">
          "Patient education: Depression in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4866.html" rel="external">
          "Patient education: Depression treatment options for adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4872.html" rel="external">
          "Patient education: Electroconvulsive therapy (ECT) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29355745">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Treatment-resistant depression typically refers to unipolar major depressive episodes  (
         <a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">
          table 1
         </a>
         ) that do not respond satisfactorily after two trials of antidepressant monotherapy at sufficient doses for sufficient duration; however, the definition has not been standardized. (See
         <a class="medical medical_review" href="/z/d/html/87498.html" rel="external">
          "Unipolar treatment-resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis", section on 'Treatment-resistant depression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – The general principles and issues that are involved in treating resistant depression in adults include confirming the diagnosis, adherence with treatment, and duration of an adequate drug trial. (See
         <a class="medical medical_review" href="/z/d/html/119986.html" rel="external">
          "Unipolar depression in adults: General principles of treating resistant depression"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with mild to moderate depression
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial approach: Augmentation
         </strong>
         – Our initial approach in patients with resistant, mild to moderate major depression is to augment the current antidepressant with a second medication, psychotherapy, or repetitive transcranial magnetic stimulation (TMS)  (
         <a class="graphic graphic_algorithm graphicRef142553" href="/z/d/graphic/142553.html" rel="external">
          algorithm 1
         </a>
         ). However, switching treatments is a reasonable alternative to augmentation. Patients who cannot tolerate an adequate dose of the initial antidepressant should switch to another antidepressant. (See
         <a class="local">
          'Treatment algorithm'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Many patients with resistant depression can tolerate the initial antidepressant, and opt for add-on pharmacotherapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients who prioritize efficacy, we suggest add-on treatment with a second-generation antipsychotic (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is a reasonable alternative to a second-generation antipsychotic.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Among second-generation antipsychotics, our general order of preference is
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         , and less often,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         , or
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         . (See
         <a class="local">
          'Choosing a drug'
         </a>
         above and
         <a class="local">
          'Patients who prioritize efficacy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients who prioritize tolerability, we suggest augmentation with a second antidepressant from a different class as first-step treatment. (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We avoid using monoamine oxidase inhibitors (MAOIs) as the second antidepressant. However, thyroid hormone is a reasonable alternative to a second antidepressant from a different class. (See
         <a class="local">
          'Choosing a drug'
         </a>
         above and
         <a class="local">
          'Patients who prioritize tolerability'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For patients with resistant depression who augment antidepressants with a second drug and do not respond, we generally provide one to two additional courses of augmentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Next step treatments: Switching
         </strong>
         – For patients with resistant depression who do not respond to augmentation with a second drug, we generally switch to a different antidepressant or to psychotherapy or repetitive TMS. When switching to a different antidepressant, we typically maintain the current adjunctive drug. (See
         <a class="local">
          'Treatment algorithm'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Our approach in patients who switch antidepressants is to select a drug from a different class  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 7
         </a>
         ) rather than the same class. In choosing a new antidepressant for patients who fail a selective serotonin reuptake inhibitor (SSRI), our general order of preference is serotonin-norepinephrine reuptake inhibitors, atypical antidepressants, tricyclics, and MAOIs  (
         <a class="graphic graphic_algorithm graphicRef131935" href="/z/d/graphic/131935.html" rel="external">
          algorithm 2
         </a>
         ). However, it is reasonable to use these drugs in a different sequence or to switch to a different SSRI or a serotonin modulator at any point in the sequence. (See
         <a class="local">
          'Antidepressants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with severe depression
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial approach
         </strong>
         – For patients with treatment-resistant, severe, nonpsychotic unipolar major depression, we suggest intravenous
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         rather than electroconvulsive therapy (ECT) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). A reasonable alternative to ketamine is
         <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">
          esketamine
         </a>
         . In addition, it is reasonable to use ECT rather than ketamine/esketamine. (See
         <a class="local">
          'Initial approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Next step
         </strong>
         – If severe, treatment-resistant, nonpsychotic does not respond to
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , next step treatment is ECT. (See
         <a class="local">
          'Next step treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H73994235">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Wayne Katon, MD, and Paul Ciechanowski, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markowitz JC, Wright JH, Peeters F, et al. The Neglected Role of Psychotherapy for Treatment-Resistant Depression. Am J Psychiatry 2022; 179:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry 2018; 75:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Mann JJ. Depression. Lancet 2018; 392:2299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021; 55:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qaseem A, Owens DK, Etxeandia-Ikobaltzeta I, et al. Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med 2023; 176:239.
          </a>
         </li>
         <li class="breakAll">
          VA/DoD Clinical Practice Guideline. (2022). The Management of Major Depressive Disorder. Washington, DC: U.S. Government Printing Office.
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarron RM, Shapiro B, Rawles J, Luo J. Depression. Ann Intern Med 2021; 174:ITC65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016; 61:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies P, Ijaz S, Williams CJ, et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev 2019; 12:CD010557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kini V, Ho PM. Interventions to Improve Medication Adherence: A Review. JAMA 2018; 320:2461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyce P, Hopwood M, Morris G, et al. Switching antidepressants in the treatment of major depression: When, how and what to switch to? J Affect Disord 2020; 261:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wisniewski SR, Fava M, Trivedi MH, et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry 2007; 164:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition. Am J Psychiatry 2010; 167 (supplement):1.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. http://psychiatryonline.org/guidelines.aspx (Accessed on April 17, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015; 29:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre RS, Suppes T, Tandon R, Ostacher M. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. J Clin Psychiatry 2017; 78:703.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline (ng222). June 29, 2022. https://www.nice.org.uk/guidance/ng222 (Accessed on June 16, 2023).
         </li>
         <li class="breakAll">
          National Institute for Health &amp; Clinical Excellence. The Treatment and Management of Depression in Adults (updated edition). National Clinical Practice Guideline 90, 2010. http://www.nice.org.uk/ (Accessed on December 24, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen RA, Dusetzina SB, Ellis AR, et al. Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. Gen Hosp Psychiatry 2012; 34:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crismon ML, Trivedi M, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999; 60:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009; 60:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamed S, Johnson GR, Chen P, et al. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017; 318:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zisook S, Johnson GR, Tal I, et al. General Predictors and Moderators of Depression Remission: A VAST-D Report. Am J Psychiatry 2019; 176:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Trivedi MH, Nelson JC, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry 2008; 10:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M. Lessons Learned From the VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) Study. JAMA 2017; 318:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han C, Wang SM, Kwak KP, et al. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study. J Psychiatr Res 2015; 66-67:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenze EJ, Mulsant BH, Roose SP, et al. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. N Engl J Med 2023; 388:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang Y, Yuan C, Xu Y, et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol 2011; 31:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang Y, Yuan C, Xu Y, et al. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. J Clin Psychopharmacol 2010; 30:357.
          </a>
         </li>
         <li class="breakAll">
          Santaguida P, MacQueen G, Keshavarz H, et al. Treatment for Depression After Unsatisfactory Response to SSRIs. Comparative Effectiveness Review No. 62. (Prepared by McMaster University Evidence-based Practice Center under Contract No. HHSA 290 2007 10060 I.). AHRQ Publication No.12-EHC050-EF, Agency for Healthcare Research and Quality; Department of Health and Human Services, Rockville, MD 2012.
         </li>
         <li class="breakAll">
          Agency for Healthcare Research and Quality. Treatment for Depression after Unsatisfactory Response to SSRIs. Comparative Effectiveness Review No. 62. April, 2012. http://effectivehealthcare.ahrq.gov/ (Accessed on December 11, 2012).
         </li>
         <li class="breakAll">
          Gaynes BN, Lux L, Lloyd S, et al. Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults. Comparative Effectiveness Review No. 33. AHRQ Publication No. 11-EHC056-EF, Agency for Healthcare Research and Quality; Department of Health and Human Services, Rockville, MD 2011.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaynes BN, Dusetzina SB, Ellis AR, et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol 2012; 32:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro V, Boulahfa I, Obach A, et al. Switching to Imipramine Versus Add-on Mirtazapine in Venlafaxine-Resistant Major Depression: A 10-Week Randomized Open Study. J Clin Psychopharmacol 2019; 39:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baethge C. Guideline advice on second-step antidepressant treatment: The evidence for IDAS in MIDAS. Bipolar Disord 2021; 23:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strawbridge R, Carter B, Marwood L, et al. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry 2019; 214:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunlop BW, LoParo D, Kinkead B, et al. Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression. Am J Psychiatry 2019; 176:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greer TL, Trombello JM, Rethorst CD, et al. IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY. Depress Anxiety 2016; 33:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danielsson L, Papoulias I, Petersson EL, et al. Exercise or basic body awareness therapy as add-on treatment for major depression: a controlled study. J Affect Disord 2014; 168:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preskorn SH. Treatment options for the patient who does not respond well to initial antidepressant therapy. J Psychiatr Pract 2009; 15:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009; 70 Suppl 6:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011; 71:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLachlan G. Treatment resistant depression: what are the options? BMJ 2018; 363:k5354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Dell'osso L, Kasper S, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord 2013; 151:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015; 76:e487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 2015; 76:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015; 76:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papadimitropoulou K, Vossen C, Karabis A, et al. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin 2017; 33:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan Y, Yang X, Wang M, et al. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. Psychol Med 2022; 52:2224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 2017; 7:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez-Egea E, Miller B, Garcia-Rizo C, et al. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol 2011; 31:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010; 23:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jawad MY, Alnefeesi Y, Lui LMW, et al. Olanzapine and samidorphan combination treatment: A systematic review. J Affect Disord 2022; 301:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang HR, Woo YS, Ahn HS, et al. Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials. Int J Neuropsychopharmacol 2015; 18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009; 70:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010; 71:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheon EJ, Lee KH, Park YW, et al. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study. J Clin Psychopharmacol 2017; 37:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kishimoto T, Hagi K, Kurokawa S, et al. Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. Psychol Med 2023; 53:4064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zall H, Therman PG, Myers JM. Lithium carbonate: a clinical study. Am J Psychiatry 1968; 125:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC, Baumann P, Delucchi K, et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014; 168:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henssler J, Alexander D, Schwarzer G, et al. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry 2022; 79:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro V, Boulahfa I, Obach A, et al. Lithium Augmentation Versus Citalopram Combination in Imipramine-Resistant Major Depression: A 10-Week Randomized Open-Label Study. J Clin Psychopharmacol 2019; 39:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prange AJ Jr, Wilson IC, Rabon AM, Lipton MA. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969; 126:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper-Kazaz R, Apter JT, Cohen R, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McPherson S, Cairns P, Carlyle J, et al. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand 2005; 111:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trivedi RB, Nieuwsma JA, Williams JW Jr. Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. J Gen Intern Med 2011; 26:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry 2020; 19:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parikh SV, Quilty LC, Ravitz P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments. Can J Psychiatry 2016; 61:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ijaz S, Davies P, Williams CJ, et al. Psychological therapies for treatment-resistant depression in adults. Cochrane Database Syst Rev 2018; 5:CD010558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Bronswijk S, Moopen N, Beijers L, et al. Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression. Psychol Med 2019; 49:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 2013; 381:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakagawa A, Mitsuda D, Sado M, et al. Effectiveness of Supplementary Cognitive-Behavioral Therapy for Pharmacotherapy-Resistant Depression: A Randomized Controlled Trial. J Clin Psychiatry 2017; 78:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray G, Michalak EE, Axler A, et al. Relief of chronic or resistant depression (Re-ChORD): a pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression. J Affect Disord 2010; 123:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonagy P, Rost F, Carlyle JA, et al. Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS). World Psychiatry 2015; 14:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Town JM, Abbass A, Stride C, Bernier D. A randomised controlled trial of Intensive Short-Term Dynamic Psychotherapy for treatment resistant depression: the Halifax Depression Study. J Affect Disord 2017; 214:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu B, Zhang Y, Zhang L, Li L. Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study. BMC Psychiatry 2014; 14:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. Can J Psychiatry 2016; 61:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008; 63:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006; 67:1836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC, Spyker DA. Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014. Am J Psychiatry 2017; 174:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köhler-Forsberg O, Larsen ER, Buttenschøn HN, et al. Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. Br J Psychiatry 2019; 215:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002; 59:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006; 163:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME. The role of monoamine oxidase inhibitors in depression treatment guidelines. J Clin Psychiatry 2012; 73 Suppl 1:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fekadu A, Rane LJ, Wooderson SC, et al. Prediction of longer-term outcome of treatment-resistant depression in tertiary care. Br J Psychiatry 2012; 201:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suchting R, Tirumalajaru V, Gareeb R, et al. Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis. J Affect Disord 2021; 282:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schosser A, Serretti A, Souery D, et al. European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol 2012; 22:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakagome K, Yokoi Y, Nakagawa A, et al. Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial. J Affect Disord 2021; 282:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res 2019; 111:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. J Affect Disord 2018; 241:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iosifescu DV. Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress. JAMA 2022; 328:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oslin DW, Lynch KG, Shih MC, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA 2022; 328:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bschor T, Kern H, Henssler J, Baethge C. Switching the Antidepressant After Nonresponse in Adults With Major Depression: A Systematic Literature Search and Meta-Analysis. J Clin Psychiatry 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007; 164:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schatzberg AF, Rush AJ, Arnow BA, et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry 2005; 62:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mutz J, Vipulananthan V, Carter B, et al. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ 2019; 364:l1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017; 74:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrade C. Ketamine for Depression, 2: Diagnostic and Contextual Indications. J Clin Psychiatry 2017; 78:e555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh I, Morgan C, Curran V, et al. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry 2017; 4:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swainson J, McGirr A, Blier P, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. Can J Psychiatry 2021; 66:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrade C. Ketamine for Depression, 3: Does Chirality Matter? J Clin Psychiatry 2017; 78:e674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2018; 75:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry 2018; 175:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med 2023; 388:2315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinoza RT, Kellner CH. Electroconvulsive Therapy. N Engl J Med 2022; 386:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reif A, Bitter I, Buyze J, et al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. N Engl J Med 2023; 389:1298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhee TG, Shim SR, Forester BP, et al. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. JAMA Psychiatry 2022; 79:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon V, Varadharajan N, Faheem A, Andrade C. Ketamine vs Electroconvulsive Therapy for Major Depressive Episode: A Systematic Review and Meta-analysis. JAMA Psychiatry 2023; 80:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry 2015; 172:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Byrow Y, Cassidy F, et al. Ketamine: stimulating antidepressant treatment? BJPsych Open 2016; 2:e5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman R. Ketamine and ECT in Depression - Risks and Rewards. N Engl J Med 2023; 388:2389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kellner CH, Greenberg RM, Murrough JW, et al. ECT in treatment-resistant depression. Am J Psychiatry 2012; 169:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allan C, Kalu UG, Sexton CE, Ebmeier KP. Transcranial stimulation in depression. Br J Psychiatry 2012; 200:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med 2007; 357:1939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel M, Patel S, Hardy DW, et al. Should electroconvulsive therapy be an early consideration for suicidal patients? J ECT 2006; 22:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brådvik L, Berglund M. Long-term treatment and suicidal behavior in severe depression: ECT and antidepressant pharmacotherapy may have different effects on the occurrence and seriousness of suicide attempts. Depress Anxiety 2006; 23:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kellner CH, Fink M, Knapp R, et al. Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am J Psychiatry 2005; 162:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT 2004; 20:13.
          </a>
         </li>
         <li class="breakAll">
          FDA Executive Summary: Prepared for the January 27-28, 2011 meeting of the Neurological Devices Panel. Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM240933.pdf (Accessed on May 25, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT 2003; 19:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folkerts HW, Michael N, Tölle R, et al. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression -- a randomized study. Acta Psychiatr Scand 1997; 96:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010; 71:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berlim MT, Van den Eynde F, Daskalakis ZJ. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. Depress Anxiety 2013; 30:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Health Quality Ontario. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ont Health Technol Assess Ser 2016; 16:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ren J, Li H, Palaniyappan L, et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2014; 51:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen PE, Ravnkilde B, Videbech P, et al. Low-frequency repetitive transcranial magnetic stimulation inferior to electroconvulsive therapy in treating depression. J ECT 2011; 27:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreines JL, McClintock SM, Holtzheimer PE. Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review. Brain Stimul 2011; 4:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001; 285:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006; 63:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7 Suppl 1:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry 2010; 167:1.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition http://psychiatryonline.org/guidelines.aspx (Accessed on December 19, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amsterdam JD, Kim TT. Relative Effectiveness of Monoamine Oxidase Inhibitor and Tricyclic Antidepressant Combination Therapy for Treatment-Resistant Depression. J Clin Psychopharmacol 2019; 39:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor RW, Coleman JRI, Lawrence AJ, et al. Predicting clinical outcome to specialist multimodal inpatient treatment in patients with treatment resistant depression. J Affect Disord 2021; 291:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker WA, Scott J, Eccleston D. The Newcastle chronic depression study: results of a treatment regime. Int Clin Psychopharmacol 1987; 2:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baghai TC, Blier P, Baldwin DS, et al. General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2011; 261 Suppl 3:207.
          </a>
         </li>
         <li class="breakAll">
          NICE. National Institute for Health and Care Excellence. Implanted vagus nerve stimulation for treatment-resistant depression. Interventional procedures guidance [IPG679]. Published August 12, 2020. https://www.nice.org.uk/guidance/ipg679 (Accessed on May 03, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carreno FR, Frazer A. Vagal Nerve Stimulation for Treatment-Resistant Depression. Neurotherapeutics 2017; 14:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller HHO, Moeller S, Lücke C, et al. Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use. Front Neurosci 2018; 12:239.
          </a>
         </li>
         <li class="breakAll">
          Summary of Safety and Effectiveness Data. July, 2005. https://www.accessdata.fda.gov/cdrh_docs/pdf/p970003s050b.pdf (Accessed on May 05, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dell'Osso B, Oldani L, Grancini B, et al. Ten-year outcome of vagus nerve stimulation-implanted patients with treatment-resistant depression: two Italian cases. Neuropsychiatr Dis Treat 2018; 14:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013; 14:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yehuda R, Lehrner A. Psychedelic Therapy-A New Paradigm of Care for Mental Health. JAMA 2023; 330:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 2021; 384:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2021; 78:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med 2022; 387:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA 2023; 330:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nutt D, Carhart-Harris R. The Current Status of Psychedelics in Psychiatry. JAMA Psychiatry 2021; 78:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry 2016; 3:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenblat JD, Husain MI, Lee Y, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Can J Psychiatry 2023; 68:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodwin GM, Malievskaia E, Fonzo GA, Nemeroff CB. Must Psilocybin Always "Assist Psychotherapy"? Am J Psychiatry 2024; 181:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016; 30:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016; 30:1165.
          </a>
         </li>
         <li class="breakAll">
          Australian Government. Department of Health and Aged Care. Therapeutic Goods Administration. https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin (Accessed on August 21, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagele P, Duma A, Kopec M, et al. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. Biol Psychiatry 2015; 78:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy SH, Milev R, Giacobbe P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord 2009; 117 Suppl 1:S44.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14685 Version 62.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17074942" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12813115" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12813115" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35105164" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The Neglected Role of Psychotherapy for Treatment-Resistant Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29450462" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14399272" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A rating scale for depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/444788" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A new depression scale designed to be sensitive to change.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30396512" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36689752" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36689752" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33971098" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27486148" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31846068" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pharmacological interventions for treatment-resistant depression in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16079372" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Adherence to medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30561486" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Interventions to Improve Medication Adherence: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31630037" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Switching antidepressants in the treatment of major depression: When, how and what to switch to?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17475734" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Acceptability of second-step treatments to depressed outpatients: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25969470" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28682531" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28682531" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28682531" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22079151" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10192589" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19880458" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28697253" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30947531" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : General Predictors and Moderators of Depression Remission: A VAST-D Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19287552" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28697241" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Lessons Learned From the VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26013203" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36867173" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21869688" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20571433" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20571433" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20571433" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20571433" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22198447" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30516574" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Switching to Imipramine Versus Add-on Mirtazapine in Venlafaxine-Resistant Major Depression: A 10-Week Randomized Open Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33783075" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Guideline advice on second-step antidepressant treatment: The evidence for IDAS in MIDAS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30457075" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30764648" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27164293" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25043321" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Exercise or basic body awareness therapy as add-on treatment for major depression: a controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461393" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Treatment options for the patient who does not respond well to initial antidepressant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19922740" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21175239" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19687129" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17592920" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8792761" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30563939" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Treatment resistant depression: what are the options?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23810357" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25919841" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26301771" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26301701" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28035869" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35993319" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28101322" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337666" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21346617" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Metabolic effects of olanzapine in patients with newly diagnosed psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20838345" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cardiovascular aspects of antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35007644" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Olanzapine and samidorphan combination treatment: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25770098" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19284928" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20361905" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28129308" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35510505" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5711819" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Lithium carbonate: a clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25069082" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35171215" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30925498" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Lithium Augmentation Versus Citalopram Combination in Imipramine-Resistant Major Depression: A 10-Week Randomized Open-Label Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4185164" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Enhancement of imipramine antidepressant activity by thyroid hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16946176" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17548749" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15819726" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : The effectiveness of psychological treatments for treatment-resistant depression: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21184287" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31922679" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27486150" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29761488" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Psychological therapies for treatment-resistant depression in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30139408" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23219570" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28252882" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Effectiveness of Supplementary Cognitive-Behavioral Therapy for Pharmacotherapy-Resistant Depression: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19896200" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Relief of chronic or resistant depression (Re-ChORD): a pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26407787" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28266318" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : A randomised controlled trial of Intensive Short-Term Dynamic Psychotherapy for treatment resistant depression: the Halifax Depression Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25433539" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27486154" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17919460" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17194261" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16554525" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28135844" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30698114" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11879161" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16816220" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22951237" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The role of monoamine oxidase inhibitors in depression treatment guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22955008" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Prediction of longer-term outcome of treatment-resistant depression in tertiary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33601690" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22464339" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33601673" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12363125" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30677646" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30149336" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35819435" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35819423" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27929611" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Switching the Antidepressant After Nonresponse in Adults With Major Depression: A Systematic Literature Search and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17475733" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15867104" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30917990" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28249076" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28570803" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Ketamine for Depression, 2: Diagnostic and Contextual Indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28395988" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33174760" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété(Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28682536" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Ketamine for Depression, 3: Does Chirality Matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29282469" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29656663" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37224232" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35172057" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Electroconvulsive Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37792613" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36260324" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37043224" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Ketamine vs Electroconvulsive Therapy for Major Depressive Episode: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26423481" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27703782" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Ketamine: stimulating antidepressant treatment?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37224235" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Ketamine and ECT in Depression - Risks and Rewards.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23212054" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : ECT in treatment-resistant depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22215863" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Transcranial stimulation in depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17989386" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Electroconvulsive therapy for depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16801826" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Should electroconvulsive therapy be an early consideration for suicidal patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16315268" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Long-term treatment and suicidal behavior in severe depression: ECT and antidepressant pharmacotherapy may have different effects on the occurrence and seriousness of suicide attempts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15863801" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Relief of expressed suicidal intent by ECT: a consortium for research in ECT study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15087991" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Efficacy of ECT in depression: a meta-analytic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15087991" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Efficacy of ECT in depression: a meta-analytic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12972983" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : A meta-analysis of electroconvulsive therapy efficacy in depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12642045" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9395150" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Electroconvulsive therapy vs. paroxetine in treatment-resistant depression -- a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20361902" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23349112" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27099642" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24556538" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20351570" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Low-frequency repetitive transcranial magnetic stimulation inferior to electroconvulsive therapy in treating depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21255751" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11255384" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17146008" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9597346" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Practice guideline for the treatment of patients with major depressive disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Practice guideline for the treatment of patients with major depressive disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31688401" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Relative Effectiveness of Monoamine Oxidase Inhibitor and Tricyclic Antidepressant Combination Therapy for Treatment-Resistant Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34044338" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Predicting clinical outcome to specialist multimodal inpatient treatment in patients with treatment resistant depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3121718" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : The Newcastle chronic depression study: results of a treatment regime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16139580" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22033583" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22033583" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28585221" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Vagal Nerve Stimulation for Treatment-Resistant Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29692707" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29692707" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29636616" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Ten-year outcome of vagus nerve stimulation-implanted patients with treatment-resistant depression: two Italian cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23879318" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37651148" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Psychedelic Therapy-A New Paradigm of Care for Mental Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33852780" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Trial of Psilocybin versus Escitalopram for Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33146667" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36322843" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37651119" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32725172" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : The Current Status of Psychedelics in Psychiatry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27067625" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35975555" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37434509" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Must Psilocybin Always "Assist Psychotherapy"?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27909165" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27909164" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27909164" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25577164" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19656575" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
